Purpose: For patients with rheumatoid arthritis (RA) who do not respond or lose response to anti-tumor necrosis factor (TNF) biologics, switching to a different anti-TNF can be an effective means to manage symptoms and disease progression. This study examined the utilization and effectiveness of intravenous golimumab within a real-world population of patients with RA switching directly from infliximab, a potent anti-TNF.
Methods: Patient charts (n = 113) were collected from five US-based rheumatology practices. Patient demographics, treatment characteristics, infliximab and intravenous golimumab utilization data, and Clinical Disease Activity Index (CDAI), Patient Global Assessment (PtGA), Physician Global Assessment (PhGA), and Routine Assessment of Patient Index Data (RAPID3) scores were extracted from charts. The effectiveness of intravenous golimumab was assessed by comparing disease activity status pre- and post-initiation of intravenous golimumab therapy.
Findings: Significant decreases in patient disease activity were observed following treatment with intravenous golimumab. Mean CDAI and PhGA scores significantly decreased, and a significantly increased proportion of the population exhibited low disease activity or remission in the post intravenous golimumab period (p < 0.05). Limited changes were observed through the RAPID3 and PtGA.
Conclusions: Findings from this study indicate that intravenous golimumab is effective in managing RA in a population of patients switching directly from infliximab (mean last dose 7.4 mg/kg).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131122 | PMC |
| http://dx.doi.org/10.1007/s40268-018-0240-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravenous Golimumab in the Treatment of Juvenile Idiopathic Arthritis and Its Associated Uveitis.
Ocul Immunol Inflamm
August 2024
Department of Ophthalmology, University of Florida, Gainesville, Florida, USA.
Article Synopsis
- The study evaluated the effectiveness and safety of intravenous golimumab for treating anterior uveitis in patients with juvenile idiopathic arthritis (JIA).
- A retrospective analysis of 13 patients revealed significant improvements in anterior chamber reaction and flare-ups after 12 months of treatment compared to the year prior.
- Most patients (84.6%) responded positively to the medication, although there were some adverse effects, highlighting the need for more extensive research to confirm the results.
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study.
J Rheumatol
November 2024
A. Martini, MD, Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy.
Objective: To report pharmacokinetics (PK), immunogenicity, clinical effect, and safety of intravenous (IV) golimumab in children with active polyarticular-course juvenile idiopathic arthritis (pcJIA) who participated in A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy (GO-VIVA)'s open-label, long-term extension (LTE) through week 252.
Methods: GO-VIVA participants who continued IV golimumab (80 mg/m every 8 weeks) after week 52 were included. PK and safety were assessed through week 244 (last dose) and week 252, respectively, and clinical response through week 116.
Drug therapy in juvenile spondyloarthritis.
Curr Opin Rheumatol
July 2024
Division of Rheumatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Article Synopsis
- This review discusses recent advancements in treating juvenile spondyloarthritis, focusing on enthesitis-related arthritis and juvenile psoriatic arthritis.
- New biologic drugs beyond tumor necrosis factor inhibitors, such as IL-17 blockers and Janus kinase inhibitors, have shown promising safety and efficacy in clinical settings.
- There's an ongoing need for robust real-world data and registry studies to further understand the effectiveness of these treatments and to develop strategies for reducing medication dosages when appropriate.
A Case Report: Unveiling the Underlying Cause of Recurrent Pericarditis in a Patient With Undifferentiated Connective Tissue Disease.
Cureus
February 2024
Internal Medicine, Adelante Healthcare, Phoenix, USA.
Undifferentiated connective tissue disease (UCTD) is a condition characterized by symptoms and laboratory findings related to various systematic autoimmune diseases. Severe symptoms like chest pain in patients with UCTD could suggest an underlying secondary condition, such as pericarditis. Our case involves a 36-year-old woman with a history of UCTD and recently diagnosed rheumatoid arthritis (RA) who presented with persistent sub-sternal chest pain and pressure that began three weeks ago.
View Article and Find Full Text PDFClinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Therap Adv Gastroenterol
January 2024
Gastroenterology and Hepatology Department, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet s/n, Badalona, Catalonia 08916, Spain.
Article Synopsis
- Infliximab is considered the most effective anti-TNF treatment for ulcerative colitis (UC), but there is limited information on its use as a second anti-TNF option.
- This study analyzed 473 UC patients to compare outcomes between those receiving their first anti-TNF treatment via intravenous (IV) versus subcutaneous (SC) routes.
- Results showed similar clinical response and remission rates after 14 and 52 weeks, suggesting that while a second anti-TNF can be effective, prior failure of the first anti-TNF significantly impacts long-term success.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!